<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Forty-three patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) received treatment with oral <z:chebi fb="0" ids="4911">etoposide</z:chebi> 50 mg/day for 21 consecutive days every 4 weeks </plain></SENT>
<SENT sid="1" pm="."><plain>Eighteen patients (42%) experienced hematological responses, including 12 of 17 (70%) patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Three of five <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> patients who failed treatment with <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> experienced major hematological responses with oral <z:chebi fb="0" ids="4911">etoposide</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Median response duration exceeded 9 months (range: 4-49 + months), and one patient remains in an unmaintained complete remission for 4 years </plain></SENT>
<SENT sid="4" pm="."><plain>Toxicity included <z:hpo ids='HP_0002018'>nausea</z:hpo>/<z:hpo ids='HP_0002013'>vomiting</z:hpo> in five patients, <z:hpo ids='HP_0001945'>fever</z:hpo> (four patients), <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> (three patients), mucositis (two patients), and <z:hpo ids='HP_0002039'>anorexia</z:hpo> (two patients) </plain></SENT>
<SENT sid="5" pm="."><plain>Two patients had grade 4 <z:hpo ids='HP_0001875'>neutropenia</z:hpo> with <z:hpo ids='HP_0100806'>sepsis</z:hpo> necessitating treatment withdrawal </plain></SENT>
<SENT sid="6" pm="."><plain>We conclude that low-dose oral <z:chebi fb="0" ids="4911">etoposide</z:chebi> has remitting activity in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and is an effective treatment alternative for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> </plain></SENT>
</text></document>